Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.5007
Oct 26 • 3:59 PM ET Dollar change+0.0897 Percentage change(21.82%)
Aftermarket Close
0.5299
Aftermarket • 7:59 PM ET Dollar change+0.0292 Percentage change(5.83%)
Oct 26, 11:02 AMMedicare EsoGuard payments extend Lucid Diagnostics 27% higher in Monday trade
Index
RUT
Market Cap
101.76M
Enterprise Value
93.27M
Income
-65.01M
Sales
5.45M
Book/sh
0.06
Cash/sh
0.16
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
82
IPO
Oct 14, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
18.67
P/B
8.74
P/C
3.05
P/FCF
-
EV/EBITDA
-
EV/Sales
17.11
Quick Ratio
1.30
Current Ratio
1.33
Debt/Eq
2.28
LT Debt/Eq
0.05
Option/Short
No / Yes
EPS (ttm)
-0.47
EPS next Y
-0.18
EPS next Q
-0.06
EPS this Y
37.21%
EPS next Y
31.48%
EPS next 5Y
28.07%
EPS past 3/5Y
23.61% -25.34%
Sales past 3/5Y
131.97% -
EPS Y/Y TTM
55.16%
Sales Y/Y TTM
24.89%
EPS Q/Q
-0.88%
Sales Q/Q
26.74%
Insider Own
21.20%
Insider Trans
0.57%
Inst Own
30.28%
Inst Trans
17.20%
ROA
-134.66%
ROE
-556.27%
ROIC
-457.21%
Gross Margin
-37.78%
Oper. Margin
-930.85%
Profit Margin
-1193.87%
SMA20
-8.75%
SMA50
-34.11%
SMA200
-51.83%
Trades
Shs Outstand
190.76M
Shs Float
160.15M
52W High
1.63 -69.27%
52W Low
0.30 65.25%
Volatility
21.88% 15.40%
ATR (14)
0.08
RSI (14)
41.64
Beta
1.17
Rel Volume
11.16
Avg Volume
3.91M
Volume
43,581,979
Perf Week
32.67%
Perf Month
-39.38%
Perf Quarter
-45.24%
Perf Half Y
-52.76%
Perf YTD
-54.06%
Perf Year
-60.88%
Perf 3Y
-61.48%
Perf 5Y
-94.94%
Perf 10Y
-
Prev Close
0.41
Price
0.50
Change %
21.82%
Date Action Analyst Rating Change Price Target Change
Dec-27-21Initiated Ascendiant Capital Markets Buy $16
Nov-08-21Initiated Needham Buy $17
Nov-08-21Initiated Cantor Fitzgerald Overweight $21
Nov-08-21Initiated BTIG Research Buy $14
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matheis DennisDirectorMay 20 '26Buy1.00245,000245,2701,033,443May 21 04:20 PM
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.
Chairman & CEODr. Lishan Aklog M.D.
President & COOMr. Shaun M. O'Neill M.B.A.
Chief Financial OfficerMr. Dennis M. McGrath CPA
General Counsel & SecretaryMr. Michael Adam Gordon
Ph.D.Dr. Sanford D. Markowitz M.D.